AI Drug Discovery for Pharma and Biotech

Drug discovery

2

drugs

With orphan designations

Overview

Hereditary orotic aciduria (HOA) is a rare autosomal recessive disorder caused by deficiency of uridine monophosphate synthase (UMPS), disrupting de novo pyrimidine synthesis. It presents with megaloblastic anemia, growth retardation, developmental delay, and excessive urinary orotic acid excretion, which may lead to crystalluria and urinary obstruction. Untreated cases risk irreversible neurodevelopmental disabilities. Diagnosis relies on elevated urine orotic acid, genetic testing for UMPS mutations, and exclusion of urea cycle defects. Early treatment with uridine supplementation (e.g., uridine triacetate) prevents complications [1][7][11][14].

Population

  • Incidence <1:1,000,000, with <30 reported cases globally [1][3][14].

  • Higher prevalence in consanguineous populations (e.g., Bedouin communities) [1][2].

  • Often identified via newborn screening programs detecting elevated orotic acid in dried blood spots [14].

Burden

  • Untreated cases develop refractory anemia, immunodeficiency, and severe intellectual disability [1][11].

  • Chronic crystalluria increases risk of nephrolithiasis and obstructive uropathy [7][9].

  • High economic burden due to orphan drug costs ($22,500/30 packets for Xuriden) and lifelong management [3][8].

Therapies

  • Uridine triacetate (Xuriden): FDA-approved oral therapy (60–120 mg/kg/day) to bypass UMPS deficiency, restoring pyrimidine levels and preventing anemia/neurodevelopmental sequelae [3][8][16].

  • Lifelong therapy required; early initiation critical for optimal outcomes [14][18].

  • No established alternative treatments; hematologic monitoring and genetic counseling recommended [1][7].

Categories: rare genetic diseases, rare hematological diseases, rare inborn errors of metabolism, rare neurological diseases

Research Papers

43 drug discovery papers about Hereditary orotic aciduria. Recent publications:

43 drug discovery papers about Hereditary orotic aciduria. Recent publications:

categories:

Small molecules

proteins
2024-12-31 | Hereditary Orotic Aciduria: an uncommon presentation in a pediatric patient

Hereditary orotic aciduria is an exceedingly rare autosomal recessive disorder and can result in significant and irreversible developmental delay if not treated promptly. Typically, this disease process presents with progressive lethargy, failure to thrive, and megaloblastic anemia. Most commonly presenting before one year of life. We report a case found in an 11-month-old child who presented with incidental neutropenia and normocytic anemia in an otherwise healthy child.

Open article ↗



proteins
2024-12-31 | Hereditary Orotic Aciduria: an uncommon presentation in a pediatric patient

Hereditary orotic aciduria is an exceedingly rare autosomal recessive disorder and can result in significant and irreversible developmental delay if not treated promptly. Typically, this disease process presents with progressive lethargy, failure to thrive, and megaloblastic anemia. Most commonly presenting before one year of life. We report a case found in an 11-month-old child who presented with incidental neutropenia and normocytic anemia in an otherwise healthy child.

Open article ↗



Access all drug discovery papers and probability of success in trials forecasts:

Access all drug discovery papers and probability of success in trials forecasts:

Drug Discovery Landscape

2 orphan drug designations for Hereditary orotic aciduria, including 1 approved therapy.

2 orphan drug designations for Hereditary orotic aciduria, including 1 approved therapy.

Drug

Therapy type

Orphan designation

Clinical trial status

Sponsor

Uridine triacetate

small molecules

EMA
2024-06-28

Phase III
Terminated

Serb

uridine triacetate

small molecules

FDA
2013-08-09

Approved
2015-09-04

BTG International Inc.

“Terminated” – programs with discontinued clinical trials, or with no updates reported for 5 years after completion or 12 years after the last trial started.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.